Adult Cancers

Breast (21 trials)

Cutaneous (7 trials)

Gastrointestinal (3 trials)

Genitourinary (18 trials)

Gynecological (6 trials)

Head and Neck (7 trials)

Malignant Hematology (10 trials)

Multiple / Ill-Defined Disease Sites (18 trials)

Neurologic Oncology (9 trials)

Thoracic (12 trials)

Other Trials (64 trials)

Total Trials = 217

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Breast > Financial Assistance and Reimbursements

189819 Health ServicesResearch

NCT03943082 Borno, Hala A Pilot Feasibility Study for Improving Patient Access to Cancer Clinical Trials (iMPACT): AFinancial Reimbursement Program for Patients in Cancer Therapeutic Clinical Trials

1-877-827-3222

Breast > Prevention

16752 ScreeningNCT02620852 Esserman, Laura The WISDOM Study (Women Informed to Screen Depending on Measures of Risk) Choy@ucsf.edu

Breast > Breast Cancer Treatment

ALLIANCE-A011502

TreatmentNCT02927249 Dixit, Niharika A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as AdjuvantTherapy for HER2 Negative Breast Cancer: The ABC Trial

Paul.Couey@ucsf.edu

Breast > Breast Cancer Treatment > Advanced Breast Cancer

18953 TreatmentNCT03519178 Rugo, Hope PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY,TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI-TUMORACTIVITY OF PF-06873600 AS A SINGLE AGENT AND IN COMBINATION WITHENDOCRINE THERAPY

claire.hooker@ucsf.edu

Breast > Breast Cancer Treatment > Early Stage Breast Cancer

167514 TreatmentNCT03094052 Chien, Jo An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients withEarly Stage HER2+ Breast Cancer Treated with Neratinib with or without Trastuzumab, andIntensive Anti-Diarrhea Prophylaxis

Amy.Deluca@ucsf.edu

16704 TreatmentNCT02872025 Esserman, Laura Testing the Ability of Pembrolizumab to Alter the Tumor Immune MicroEnvironment (TIME) ofHigh Risk DCIS

Amy.Deluca@ucsf.edu;Tristan.Loveday@ucsf.edu

ALLIANCE-A011401

TreatmentNCT02750826 Melisko, Michelle Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment ofOverweight and Obese Women with Early Breast Cancer

Amy.Deluca@ucsf.edu

Breast > Breast Cancer Treatment > Radiation

117515 TreatmentNCT01570998 Alvarado, Michael Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: ARegistry Trial of Targeted Intraoperative Radiation Therapy following Breast-ConservingSurgery

Amy.Deluca@ucsf.edu;Stig.Kreps@ucsfmedctr.org

Page 2last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Breast > Breast Cancer Treatment > Advanced Breast Cancer > ER+

177540 TreatmentNCT03280563 Rugo, Hope A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy andSafety of Multiple Immunotherapy-Based Treatment Combinations in Patients with HormoneReceptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer)

Amy.Deluca@ucsf.edu

197511 TreatmentNCT03781063 Rugo, Hope An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relativeto Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced orMetastatic ER+/HER2− Breast Cancer with an ESR1 Mutation

Amy.Deluca@ucsf.edu

19758 TreatmentNCT03901339 Rugo, Hope Phase 3 Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With HormonalReceptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic BreastCancer Who Have Failed at Least 2 Prior Chemotherapy Regimens

Amy.Deluca@ucsf.edu

177528 TreatmentNCT02947685 Chien, Jo A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib +Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy afterInduction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic BreastCancer

Amy.Deluca@ucsf.edu

19754 TreatmentNCT03858972 Rugo, Hope Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine inPatients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or MetastaticBreast Cancer Who Have Not Previously Received a Taxane

Amy.Deluca@ucsf.edu

187533 TreatmentNCT03734029 Rugo, Hope A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low,Unresectable and/or Metastatic Breast Cancer Subjects

Amy.Deluca@ucsf.edu

Breast > Breast Cancer Treatment > Early Stage Breast Cancer > Invasive

187513 Supportive CareNCT03422003 Park, Catherine Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC)for Invasive Breast Carcinoma

1-877-827-3222

Breast > Breast Cancer Treatment > Advanced Breast Cancer > HER2+

187527 TreatmentNCT03414658 Rugo, Hope A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination withAvelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients with HER2-PositiveMetastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab: The"AVIATOR" Study

Amy.Deluca@ucsf.edu

177528 TreatmentNCT02947685 Chien, Jo A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib +Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy afterInduction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic BreastCancer

Amy.Deluca@ucsf.edu

187529 TreatmentNCT03529110 Rugo, Hope A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a(Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus AdoTrastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic BreastCancer Subjects Previously Treated With Trastuzumab and Taxane

Amy.Deluca@ucsf.edu

Page 3last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Breast > Breast Cancer Treatment > Advanced Breast Cancer > Brain Metastases/leptomeningeal dz

127511 TreatmentNCT01494662 Melisko, Michelle A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Neratinib and Ado-Trastuzumab Emtansine (T-DM1) for Patients with Human Epidermal Growth Factor Receptor 2(HER2)-Positive Breast cancer and Brain Metastases

Amy.Deluca@ucsf.edu

197515 TreatmentNCT03501979 Melisko, Michelle A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination ofTucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases inHER2 Positive Breast Cancer

Amy.Deluca@ucsf.edu

17752 TreatmentNCT02915744 Melisko, Michelle A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment ofPhysician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable BrainMetastases and Have Been Previously Treated With an Anthracycline, a Taxane, andCapecitabine

Amy.Deluca@ucsf.edu

Breast > Breast Cancer Treatment > Advanced Breast Cancer > Non-Specific

187533 TreatmentNCT03734029 Rugo, Hope A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low,Unresectable and/or Metastatic Breast Cancer Subjects

Amy.Deluca@ucsf.edu

Breast > Breast Cancer Treatment > Early Stage Breast Cancer > Invasive > Neoadjuvant

097517 TreatmentNCT01042379 Chien, Jo I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response withImaging and Molecular Analysis 2)

Amy.Deluca@ucsf.edu;anika.christofferson@ucsf.edu

Page 4last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Cutaneous > Financial Assistance and Reimbursements

189819 Health ServicesResearch

NCT03943082 Borno, Hala A Pilot Feasibility Study for Improving Patient Access to Cancer Clinical Trials (iMPACT): AFinancial Reimbursement Program for Patients in Cancer Therapeutic Clinical Trials

1-877-827-3222

Cutaneous > Melanoma

18859 TreatmentNCT03820986 Daud, Adil A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy ofPembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone asFirst-line Intervention in Participants with Advanced Melanoma (LEAP-003)

Ann.Tittiger@ucsf.edu

18851 TreatmentNCT03132675 Tsai, Katy A Multicenter Phase 2, Open Label Study of Intratumoral Tavo Plus Electroporation inCombination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who AreProgressing on Either Pembrolizumab or Nivolumab Treatment (Keynote 695)

Katy.Tsai@ucsf.edu;Roman.Zingarelli@ucsf.edu;arielle.oglesby@ucsf.edu

Cutaneous > Merkel Cell Carcinoma

18861 TreatmentNCT03599713 Daud, Adil A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma(POD1UM-201)

Ann.Tittiger@ucsf.edu

Cutaneous > Melanoma > Locally Advanced/ Metastatic

18855 TreatmentNCT03484923 Daud, Adil A randomized, open-label, phase II open platform study evaluating the efficacy and safety ofnovel spartalizumab (PDR001) combinations in previously treated unresectable or metastaticmelanoma

Adil.Daud@ucsf.edu;Ann.Tittiger@ucsf.edu;Roman.Zingarelli@ucsf.edu;arielle.oglesby@ucsf.edu

Cutaneous > Melanoma > Immunotherapy

18991 TreatmentNCT03486873 Daud, Adil A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacyin Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in aPembrolizumab Trial

Adil.Daud@ucsf.edu;Roman.Zingarelli@ucsf.edu

Cutaneous > Melanoma > Immunotherapy > Immunotherapy Naïve

17854 TreatmentNCT03396952 Daud, Adil Prostaglandin Inhibition and PD-1/CTLA4 blockade in Melanoma Adil.Daud@ucsf.edu;Ann.Tittiger@ucsf.edu;arielle.oglesby@ucsf.edu

Cutaneous > Melanoma > Immunotherapy > Prior Immunotherapy

18851 TreatmentNCT03132675 Tsai, Katy A Multicenter Phase 2, Open Label Study of Intratumoral Tavo Plus Electroporation inCombination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who AreProgressing on Either Pembrolizumab or Nivolumab Treatment (Keynote 695)

Katy.Tsai@ucsf.edu;Roman.Zingarelli@ucsf.edu;arielle.oglesby@ucsf.edu

Page 5last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Gastrointestinal > Financial Assistance and Reimbursements

189819 Health ServicesResearch

NCT03943082 Borno, Hala A Pilot Feasibility Study for Improving Patient Access to Cancer Clinical Trials (iMPACT): AFinancial Reimbursement Program for Patients in Cancer Therapeutic Clinical Trials

1-877-827-3222

Gastrointestinal > Neuroendocrine Tumors (NET) > High Grade / Poorly Differentiated Neuroendocrine Carcinoma

169524 TreatmentNCT03136055 Bergsland, Emily A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High GradeNeuroendocrine Carcinomas

claire.hooker@ucsf.edu

Gastrointestinal > Neuroendocrine Tumors (NET) > High Grade / Poorly Differentiated Neuroendocrine Carcinoma > Metastatic / Unresectable

17459 TreatmentNCT02724540 Fidelman, Nicholas Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver (RETNET):A phase 2 randomized multicenter trial to compare hepatic progression-free survival followingbland embolization, lipiodol chemoembolization, and drug-eluting bead chemoembolization ofneuroendocrine liver metastases

shawn.cheng@ucsf.edu

Page 6last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Genitourinary > Financial Assistance and Reimbursements

189819 Health ServicesResearch

NCT03943082 Borno, Hala A Pilot Feasibility Study for Improving Patient Access to Cancer Clinical Trials (iMPACT): AFinancial Reimbursement Program for Patients in Cancer Therapeutic Clinical Trials

1-877-827-3222

Genitourinary > Prostate Cancer

135512 Supportive CareNCT02435472 Chan, June A Randomized Clinical Trial of Exercise versus Usual Care among Men Opting for ActiveSurveillance for Prostate Cancer (AS Exercise RCT)

1-877-827-3222

185513 DiagnosticNCT03803475 Hope, Thomas Gallium-68 PSMA-11 PET in Prostate Cancer Patients 1-877-827-3222

17553 Supportive CareNCT03397160 Carroll, Peter Pioneering Advances in Care & Education (PACE) 1-877-827-3222

175513 PreventionNCT03999151 Kenfield, Stacey A Randomized Controlled Trial of Diet & Exercise Interventions among Men with ProstateCancer - II (Prostate 8 - II)

1-877-827-3222

Genitourinary > Renal Cell Carcinoma

18952 TreatmentNCT03284385 Aggarwal, Rahul A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies claire.hooker@ucsf.edu

Genitourinary > Testicular Cancer

AGCT1531 TreatmentNCT03067181 Rangaswami, Arun A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs.Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

danielle.handler@ucsf.edu

ALLIANCE-A031102

TreatmentNCT02375204 Rangaswami, Arun A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel,Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel PlusIfosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First SalvageTreatment in Relapsed or Refractory Germ Cell Tumors

danielle.handler@ucsf.edu

Genitourinary > Prostate Cancer > Non-Metastatic Castration Sensitive (Rising PSA)

165513 TreatmentNCT03009981 Aggarwal, Rahul A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed ProstateCancer

brian.ma2@ucsf.edu;lani.bradish@ucsf.edu

Genitourinary > Bladder Cancer > Localized / Non-Muscle Invasive

14524 TreatmentNCT02451423 Fong, Lawrence A Phase II Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects with Non-MetastaticTransitional Cell Carcinoma of the Bladder

brian.ma2@ucsf.edu;lani.bradish@ucsf.edu

Genitourinary > Bladder Cancer > Localized / Muscle Invasive

14524 TreatmentNCT02451423 Fong, Lawrence A Phase II Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects with Non-MetastaticTransitional Cell Carcinoma of the Bladder

brian.ma2@ucsf.edu;lani.bradish@ucsf.edu

Page 7last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Genitourinary > Prostate Cancer > Metastatic Castration Sensitive

155513 Supportive CareCarroll, Peter A Randomized Controlled Clinical Trial of a Smartphone-Based App to Improve Urinary andSexual Function Outcomes after Robot-Assisted Laparoscopic Radical Prostatectomy Surgery

1-877-827-3222

Genitourinary > Bladder Cancer > Metastatic

175211 TreatmentNCT03288545 Friedlander, Terence A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with otheranticancer therapies for the treatment of urothelial cancer

lani.bradish@ucsf.edu

Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC)

18958 TreatmentNCT03490838 Aggarwal, Rahul A Phase 1/2 open-label, multi-center, dose-escalation study of safety, tolerability,pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligandtherapy in patients with prostate specific membrane antigen (PSMA) positive (68Ga-PSMA-R2)progressive metastatic castration-resistant prostate cancer, following previous systemictreatment

ann.chan@ucsf.edu

18954 TreatmentNCT03575819 Aggarwal, Rahul A PHASE 1 STUDY OF FOR46 ADMINISTERED EVERY 21 DAYS IN PATIENTS WITHMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

claire.hooker@ucsf.edu

175519 TreatmentNCT03503344 Aggarwal, Rahul A Randomized, Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (SBRT) inCastration-Resistant Prostate Cancer Patients with Oligometastatic Disease on PSMA-PETImaging

lani.bradish@ucsf.edu

199510 TreatmentNCT04145375 Aggarwal, Rahul Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled ina ZEN003694 Protocol

1-877-827-3222

Genitourinary > Prostate Cancer > Metastatic Castration Resistant (mCRPC) > Chemotherapy Naïve - AR Target Therapy Resistant

185511 TreatmentNCT03805594 Aggarwal, Rahul Immunogenic Priming with PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer:A Phase 1b Study of 177Lu-PSMA-617 in Combination with Pembrolizumab

lani.bradish@ucsf.edu

16557 TreatmentNCT03248570 Fong, Lawrence Phase 2 open label study of pembrolizumab in patients with metastatic castration resistantprostate cancer (mCRPC) with or without DNA damage repair defects

lani.bradish@ucsf.edu

Page 8last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Gynecological > Financial Assistance and Reimbursements

189819 Health ServicesResearch

NCT03943082 Borno, Hala A Pilot Feasibility Study for Improving Patient Access to Cancer Clinical Trials (iMPACT): AFinancial Reimbursement Program for Patients in Cancer Therapeutic Clinical Trials

1-877-827-3222

Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal

18953 TreatmentNCT03519178 Rugo, Hope PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY,TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI-TUMORACTIVITY OF PF-06873600 AS A SINGLE AGENT AND IN COMBINATION WITHENDOCRINE THERAPY

claire.hooker@ucsf.edu

Gynecological > Corpus/Endometrial

17404 TreatmentNCT02715284 Chen, Lee-may A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 MonoclonalAntibody, in Patients with Advanced Solid Tumors

1-877-827-3222

Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal > First Line

AGCT1531 TreatmentNCT03067181 Rangaswami, Arun A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs.Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

danielle.handler@ucsf.edu

Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal > Progressive/Recurrent

19401 TreatmentNCT03673124 Chen, Lee-may A Phase II Trial of Ribociclib (LEE011) plus Letrozole in Women with Recurrent Low-GradeSerous Carcinoma of the Ovary, Fallopian Tube or Peritoneum

1-877-827-3222

Gynecological > Ovarian / Fallopian Tube / Primary Peritoneal > First Line > Stage IV

NRG-GY019 TreatmentNCT04095364 Chen, Lee-may A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole VersusLetrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma ofthe Ovary or Peritoneum

1-877-827-3222

Page 9last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Head and Neck > Financial Assistance and Reimbursements

189819 Health ServicesResearch

NCT03943082 Borno, Hala A Pilot Feasibility Study for Improving Patient Access to Cancer Clinical Trials (iMPACT): AFinancial Reimbursement Program for Patients in Cancer Therapeutic Clinical Trials

1-877-827-3222

Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx)

172021 TreatmentNCT03823131 Heaton, Chase The Trifecta Study: Optimizinging Antitumor Immunity Using Tavokinogene Telseplasmid withElectroporation, Pembrolizumab, and Epacadostat in Squamous Cell Carcinoma of the Headand Neck

carter.hultman@ucsf.edu

Head and Neck > Nasopharyngeal

CTSU-NRG-HN001

TreatmentNCT02135042 Yom, Sue Randomized Phase II and Phase III Studies of Individualized Treatment for NasopharyngealCarcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

carter.hultman@ucsf.edu

Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Locoregional

162011 TreatmentNCT02769520 Algazi, Alain An open-label, phase 2 efficacy study with window of opportunity immune assessment ofpembrolizumab in relapsed, locally recurrent squamous cell carcinoma of the head and neck(SCCHN)

carter.hultman@ucsf.edu

CTSU-NRG-HN004

TreatmentNCT03258554 Yom, Sue NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736(Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Headand Neck Cancer with a Contraindication to Cisplatin

carter.hultman@ucsf.edu

Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Nasopharyngeal Carcinoma (NPC)

162010 TreatmentNCT03267498 Yom, Sue Nivolumab in Combination with Chemoradiation for Patients with Stage II-IVB NasopharyngealCarcinoma, A Phase II Study with Correlative Biomarkers

carter.hultman@ucsf.edu

CTSU-NRG-HN001

TreatmentNCT02135042 Yom, Sue Randomized Phase II and Phase III Studies of Individualized Treatment for NasopharyngealCarcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

carter.hultman@ucsf.edu

Head and Neck > Squamous Cell (Larynx, Hypopharynx, Oral Cavity, Oropharynx) > Locoregional > No Prior Therapy > Peri Operative

177018 TreatmentNCT03708224 Algazi, Alain A Phase II Study of Perioperative Immunotherapy in Patients with Advanced Non-VirallyAssociated Squamous Cell Carcinoma of the Head and Neck

Julie.McCluggage@ucsf.edu;andrew.chon@ucsf.edu

Page 10last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Malignant Hematology > Financial Assistance and Reimbursements

189819 Health ServicesResearch

NCT03943082 Borno, Hala A Pilot Feasibility Study for Improving Patient Access to Cancer Clinical Trials (iMPACT): AFinancial Reimbursement Program for Patients in Cancer Therapeutic Clinical Trials

1-877-827-3222

Malignant Hematology > Non-Hodgkin Lymphoma (NHL)

16252 OtherNCT02445222 Andreadis,Charalambos

Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 Directed CAR T-CellTherapy

Jenai.Wilmoth@ucsf.edu

ECOG-ACRIN-EA4151

TreatmentNCT03267433 Kaplan, Lawrence A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic CellTransplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone forPatients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First CompleteRemission

Jenai.Wilmoth@ucsf.edu

Malignant Hematology > Multiple Myeloma (MM) > Untreated

192513 TreatmentNCT03901963 Shah, Nina A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone asMaintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are MinimalResidual Disease Positive After Frontline Autologous Stem Cell Transplant

1-877-827-3222

Malignant Hematology > T-Cell Lymphoma > Relapsed/Refractory

19252 TreatmentNCT03770000 Ai, Weiyun An Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib (RP6530), anovel PI3K delta/gamma; dual inhibitor given in combination with a histone deacetylase (HDAC)inhibitor, Romidepsin in adult patients with relapsed/refractory T-cell Lymphoma

Jenai.Wilmoth@ucsf.edu

Malignant Hematology > Chronic Lymphocytic Leukemia (CLL) > Relapsed / Refractory

19255 TreatmentNCT03740529 Fakhri, Bita A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic LymphocyticLeukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

Jenai.Wilmoth@ucsf.edu

Malignant Hematology > Acute Myeloid Leukemia (AML) > Relapsed / Refractory

169522 TreatmentNCT03194685 Smith, Catherine A First-in-Human Phase 1/2a Study to Assess the Safety, Tolerability, Efficacy, andPharmacokinetics of FF-10101-01 in Subjects with Relapsed or Refractory Acute MyeloidLeukemia

1-877-827-3222

192514 TreatmentNCT03904251 Damon, Lloyd A Phase Ib Trial with Dose Expansion Evaluating CPX-351 plus Gemtuzumab Ozogamicin forRelapsed Acute Myelogenous Leukemia

1-877-827-3222

18259 TreatmentNCT03625505 Smith, Catherine A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax inCombination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia

Jenai.Wilmoth@ucsf.edu

Malignant Hematology > Non-Hodgkin Lymphoma (NHL) > HIV Negative > Relapsed / Refractory

19255 TreatmentNCT03740529 Fakhri, Bita A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic LymphocyticLeukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

Jenai.Wilmoth@ucsf.edu

Page 11last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Malignant Hematology > Non-Hodgkin Lymphoma (NHL) > HIV Negative > Relapsed / Refractory > Aggressive

ALLIANCE-A051301

TreatmentNCT02443077 Andreadis,Charalambos

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous StemCell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

Jenai.Wilmoth@ucsf.edu

Page 12last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Multiple / Ill-Defined Disease Sites > Financial Assistance and Reimbursements

189820 Health ServicesResearch

NCT03849742 Braunstein, Steve Ride to care - A pilot study to investigate the clinical and quality of life benefit of eliminatingtransportation barriers for disadvantaged cancer patients undergoing ambulatory palliativeradiotherapy

jamese.johnson@ucsf.edu;luchia.andemicael@ucsf.edu

189819 Health ServicesResearch

NCT03943082 Borno, Hala A Pilot Feasibility Study for Improving Patient Access to Cancer Clinical Trials (iMPACT): AFinancial Reimbursement Program for Patients in Cancer Therapeutic Clinical Trials

1-877-827-3222

Page 13last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Multiple / Ill-Defined Disease Sites > Solid Tumors

169520 TreatmentNCT01953926 Melisko, Michelle An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic HumanEpidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR GeneAmplification.

claire.hooker@ucsf.edu

18956 TreatmentNCT03590054 Aggarwal, Rahul A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination withPembrolizumab in Patients with Advanced Solid Tumor Malignancies

claire.hooker@ucsf.edu

189519 TreatmentNCT03717415 Munster, Pamela An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination WithCarboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced orMetastatic Solid Tumors

ann.chan@ucsf.edu;claire.hooker@ucsf.edu

169521 TreatmentNCT03318445 Munster, Pamela Combination Therapy of Rucaparib and Irinotecan in Cancers with Mutations in DNA Repair ann.chan@ucsf.edu;ashley.bolden@ucsf.edu

19956 TreatmentNCT03989115 McCoach, Caroline A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of theCombination of RMC-4630 with Cobimetinib in Adult Participants with Relapsed/Refractory SolidTumors and a Phase 1b Study of RMC-4630 with Osimertinib in Participants with EpidermalGrowth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell LungCancer

1-877-827-3222

169524 TreatmentNCT03136055 Bergsland, Emily A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High GradeNeuroendocrine Carcinomas

claire.hooker@ucsf.edu

AMC-095 TreatmentNCT02408861 Wang, Chia-Ching A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors withExpansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated ClassicalHodgkin Lymphoma

claire.hooker@ucsf.edu

11955 TreatmentNCT01543763 Munster, Pamela Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combinationwith PCI-24781 in Patients with Metastatic Solid Tumors

kathleen.comerford@ucsf.edu;melissa.lopez@ucsf.edu

189511 TreatmentNCT03517488 Daud, Adil A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 inSubjects With Selected Advanced Solid Tumors

ann.chan@ucsf.edu;claire.hooker@ucsf.edu

189510 TreatmentNCT03682289 Aggarwal, Rahul Phase II Trial of AZD6738 Alone and in Combination with Olaparib in Patients with SelectedSolid Tumor Malignancies

claire.hooker@ucsf.edu

18959 TreatmentNCT03678883 Munster, Pamela Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3beta) Inhibitor, as aSingle Agent and Combined With Chemotherapy, in Patients With Refractory HematologicMalignancies or Solid Tumors

ann.chan@ucsf.edu

189515 TreatmentNCT03600883 Munster, Pamela A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics,Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced SolidTumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects WithAdvanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100)

ann.chan@ucsf.edu;claire.hooker@ucsf.edu

186514 TreatmentNCT03634982 McCoach, Caroline A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in AdultParticipants with Relapsed/Refractory Solid Tumors

janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

176510 TreatmentNCT03157128 McCoach, Caroline A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RETFusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation(LIBRETTO-001)

Sanjana.Srinivasan@ucsf.edu;janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

Page 14last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

18953 TreatmentNCT03519178 Rugo, Hope PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY,TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI-TUMORACTIVITY OF PF-06873600 AS A SINGLE AGENT AND IN COMBINATION WITHENDOCRINE THERAPY

claire.hooker@ucsf.edu

18952 TreatmentNCT03284385 Aggarwal, Rahul A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies claire.hooker@ucsf.edu

Page 15last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Neurologic Oncology > Financial Assistance and Reimbursements

189819 Health ServicesResearch

NCT03943082 Borno, Hala A Pilot Feasibility Study for Improving Patient Access to Cancer Clinical Trials (iMPACT): AFinancial Reimbursement Program for Patients in Cancer Therapeutic Clinical Trials

1-877-827-3222

Neurologic Oncology > Adult Glioma (Age >= 18)

13106 DiagnosticNCT03739411 Chang, Susan Pilot Study of Safety and Feasibility of Acquiring Hyperpolarized Imaging in Patients withGliomas

Jane.Rabbitt@ucsf.edu

13108 TreatmentNCT02022644 Butowski, Nicholas A Phase I Study of Convection-Enhanced Delivery of Liposomal-Irinotecan Using Real-TimeImaging with Gadolinium In Patients with Recurrent High Grade Glioma

karishma.kumar@ucsf.edu

Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 2 (Low Grade)

15103 TreatmentNCT02549833 Taylor, Jennie Pilot Randomized Neo-adjuvant Evaluation of Poly-ICLC-Assisted Tumor Lysate Vaccines inAdult Patients with WHO Grade II Glioma

Jane.Rabbitt@ucsf.edu;Meghan.Tedesco@ucsf.edu

15108 TreatmentNCT02924038 Butowski, Nicholas Pilot Randomized Pre-Surgical Evaluation of Agonist Anti-CD27 Monoclonal AntibodyVarlilumab on Immunologic Activities of IMA950 Vaccine plus Poly-ICLC in Patients with WHOGrade II Low-Grade Glioma (LGG)

Jane.Rabbitt@ucsf.edu

Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 3 (Anaplastic)

161011 TreatmentNCT02796261 Butowski, Nicholas A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of EflornithineWith Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur AfterIrradiation and Adjuvant Temozolomide Chemotherapy

1-877-827-3222

Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 4 (Glioblastoma or Gliosarcoma) > Recurrent

181011 TreatmentNCT03295396 Butowski, Nicholas A phase II, open-label study of ONC201 in adults with recurrent high-grade glioma Jane.Rabbitt@ucsf.edu

18101 TreatmentNCT02986178 Butowski, Nicholas A Multicenter Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) inRecurrent WHO Grade IV Malignant Glioma Patients

Jane.Rabbitt@ucsf.edu

Neurologic Oncology > Adult Glioma (Age >= 18) > Grade 4 (Glioblastoma or Gliosarcoma) > Recurrent > Surgical

18108 TreatmentNCT03681028 Clarke, Jennifer Pilot Study Testing Feasibility of Individualized Therapy for Recurrent Glioblastoma 1-877-827-3222

Page 16last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Thoracic > Financial Assistance and Reimbursements

189819 Health ServicesResearch

NCT03943082 Borno, Hala A Pilot Feasibility Study for Improving Patient Access to Cancer Clinical Trials (iMPACT): AFinancial Reimbursement Program for Patients in Cancer Therapeutic Clinical Trials

1-877-827-3222

Thoracic > Sarcoma

156511 TreatmentNCT02601950 Jahan, Thierry A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Sanjana.Srinivasan@ucsf.edu;janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

Thoracic > Non-small cell Lung Cancer > By Stage > Metastatic, stage IV, or inoperable

186513 TreatmentNCT03516981 Gubens, Matthew A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

Thoracic > Non-small cell Lung Cancer > By Mutation or Histology > EGFR (epidermal growth factor receptor) Mutation

176518 TreatmentNCT03318939 Blakely, Collin A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), LocallyAdvanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

Thoracic > Non-small cell Lung Cancer > By Stage > Metastatic, stage IV, or inoperable

18653 Supportive CareNCT03375489 Rabow, Michael Comparative Effectiveness of Early Integrated Telehealth versus In-Person Palliative Care forPatients with Advanced Lung Cancer

jesus.lopez@ucsf.edu;lisa.tan@ucsf.edu

Thoracic > Non-small cell Lung Cancer > By Stage > Stage III

166520 TreatmentNCT03217071 Yom, Sue PembroX: Enhancing the Immunogenicity of Non-Small Cell Lung Cancer with Pembrolizumab+/- Stereotactic Radiotherapy Delivered in the Preoperative Window, A Randomized Phase IIStudy with Correlative Biomarkers

jamese.johnson@ucsf.edu;janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

17658 TreatmentNCT03433469 Blakely, Collin A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients with SurgicallyResectable, EGFR-Mutant Non-Small Cell Lung Cancer

Sanjana.Srinivasan@ucsf.edu;janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

Thoracic > Non-small cell Lung Cancer > By Mutation or Histology > ALK (EML4-ALK) Translocation

166512 TreatmentNCT03087448 Blakely, Collin A Phase I/II Study of Ceritinib + Trametinib in Patients with Advanced ALK-Positive Non-SmallCell Lung Cancer (NSCLC)

janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

Thoracic > Non-small cell Lung Cancer > By Stage > Stage III

176512 TreatmentNCT03088930 McCoach, Caroline ARM Study: A phase II trial to evaluate crizotinib in the neoadjuvant setting in non-small cell lung cancer patients with surgically resectable, ALK, ROS1, or MET-oncogene positive non-small cell lung cancer

Sanjana.Srinivasan@ucsf.edu;janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

Page 17last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

Thoracic > Non-small cell Lung Cancer > By Stage > Stage I/II

166520 TreatmentNCT03217071 Yom, Sue PembroX: Enhancing the Immunogenicity of Non-Small Cell Lung Cancer with Pembrolizumab+/- Stereotactic Radiotherapy Delivered in the Preoperative Window, A Randomized Phase IIStudy with Correlative Biomarkers

jamese.johnson@ucsf.edu;janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

17658 TreatmentNCT03433469 Blakely, Collin A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients with SurgicallyResectable, EGFR-Mutant Non-Small Cell Lung Cancer

Sanjana.Srinivasan@ucsf.edu;janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

176512 TreatmentNCT03088930 McCoach, Caroline ARM Study: A phase II trial to evaluate crizotinib in the neoadjuvant setting in non-small cell lung cancer patients with surgically resectable, ALK, ROS1, or MET-oncogene positive non-small cell lung cancer

Sanjana.Srinivasan@ucsf.edu;janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

Thoracic > Non-small cell Lung Cancer > By Mutation or Histology > EGFR (epidermal growth factor receptor) Mutation > 1st Line

17658 TreatmentNCT03433469 Blakely, Collin A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients with SurgicallyResectable, EGFR-Mutant Non-Small Cell Lung Cancer

Sanjana.Srinivasan@ucsf.edu;janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

Thoracic > Non-small cell Lung Cancer > By Mutation or Histology > EGFR (epidermal growth factor receptor) Mutation > 2nd Line and Above

18654 TreatmentNCT03381274 Blakely, Collin A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel CombinationTherapies in Subjects with Previously Treated Advanced EGFRm NSCLC

janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

19655 TreatmentNCT04085315 Blakely, Collin A phase I/Ib study of Alisertib in combination with Osimertinib in metastatic EGFR-mutant lungcancer

janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

Thoracic > Non-small cell Lung Cancer > By Stage > Metastatic, stage IV, or inoperable > 2nd Line and Above

166518 TreatmentNCT02954991 Blakely, Collin A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination WithNivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

Page 18last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

her Trials

16803 Supportive CareNCT03209440 Rabow, Michael Palliative Care for Elderly Outpatients jesus.lopez@ucsf.edu

180820 TreatmentNCT03416530 Mueller, Sabine ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/RefractoryPediatric H3 K27M Gliomas

1-877-827-3222

16751 Supportive CareNCT03011684 Rosen, Mitchell Fertility Preservation using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial 1-877-827-3222

19407 TreatmentNCT03894215 Ueda, Stefanie A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti PD-1) as aMonotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Womenwith Recurrent Cervical Cancer (Second Line) - RaPiDS

1-877-827-3222

18656 TreatmentNCT03410043 Blakely, Collin Randomized Phase II Trial of Local Consolidation Therapy (LCT) after Osimertinib for Patientswith EGFR Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)

janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

18208 TreatmentNCT03719690 Kang, Hyunseok A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients WithHead and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and theImpact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

carter.hultman@ucsf.edu

189520 TreatmentNCT03742895 Dhawan, Mallika A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, HomologousRecombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD)Positive Advanced Cancer

1-877-827-3222

19258 TreatmentNCT03925935 Fakhri, Bita A Phase 1, Open Label, Non-randomized, Multi-Center Trial of AB-205 in Adults withLymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

1-877-827-3222

ALLIANCE-A051701

TreatmentNCT03984448 Andreadis,Charalambos

Randomized Phase II/III Study of Venetoclax (ABT199) plus Chemoimmunotherapy forMYC/BCL2 Double-Hit and Double Expressing Lymphomas

Erika.Cavallone@ucsf.edu

160814 PreventionNCT02617407 Den Besten, Pamela Pilot Study: Oral Microbiome and Dental Plaque Control with Livionex Dental Gel in ChildrenUndergoing Hematopoietic Stem Cell Transplantation (HSCT)

janelle.urata@ucsf.edu

186517 TreatmentNCT04005144 McCoach, Caroline A phase I study of brigatinib with binimetinib in advanced ALK- or ROS1-rearranged non-smallcell lung cancer (NSCLC)

janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

182010 TreatmentNCT03669718 Algazi, Alain A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus theCombination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-PositiveOropharyngeal Cancer (OPC)

carter.hultman@ucsf.edu

19522 TreatmentNCT03785925 Koshkin, Vadim A Phase 2, Single-Arm Study of Bempegaldesleukin (NKTR-214) in Combination WithNivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients

lani.bradish@ucsf.edu

19259 TreatmentNCT03590652 Shah, Nina Phase II study of the combination of daratumumab, ixazomib, pomalidomide, anddexamethasone as salvage therapy in relapsed/refractory multiple myeloma A University ofCalifornia Hematologic Malignancies Consortium Protocol (UCHMC1809)

1-877-827-3222

Page 19last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

AAML1531 TreatmentNCT02521493 Huang, Benjamin Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome emily.theobald@ucsf.edu

19405 PreventionNCT04191967 Mungo, Chemtai Cervical Cancer Screening among HIV-Infected Women in Western Kenya: Evaluation of theSafety, Acceptability, and Efficacy of an Alternative Ablation Method for Treatment ofPrecancerous Lesions

1-877-827-3222

EA-HOPE20200129

OtherNCT04377152 Hope, Thomas Expanded Access: 68Gallium-PSMA-11 for PET Imaging of Prostate Cancer jasmine.grewal@ucsf.edu

18207 Health ServicesResearch

Russell, Marika Head and Neck Survivorship and Surveillance in Vulnerable Populations 1-877-827-3222

19205 TreatmentNCT04034225 Algazi, Alain An Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients WithASPH+ Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma ofthe Head and Neck

carter.hultman@ucsf.edu

160822 PreventionNCT02860039 Wattier, Rachel Comparison of High vs. Standard Dose Flu Vaccine in Pediatric Stem Cell TransplantRecipients

1-877-827-3222

19107 TreatmentNCT04006119 Oberheim Bush,Nancy Ann

A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination with Cemiplimab-rwlc(Libtayo®) in Subjects with Recurrent or Progressive Glioblastoma

Meghan.Tedesco@ucsf.edu

CTSU-NRG-HN005

TreatmentNCT03952585 Yom, Sue A Randomized Phase II/III Trial Of De-Intensified Radiation Therapy For Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer

carter.hultman@ucsf.edu

19958 TreatmentNCT04257110 Munster, Pamela A First-in-human, Open Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase IStudy to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of BB-1701 in Subjects with Locally Advanced/Metastatic HER2 Positive Solid Tumors

ann.chan@ucsf.edu

17755 Health ServicesResearch

Burke, Nancy Catalyzing Breast Cancer Navigation for Survivorship Support: A pilot study 1-877-827-3222

19089 TreatmentNCT03509961 Higham, Christine A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) basedconditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who arepre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS)minimal residual disease (MRD) negative

magruderk@radonc.ucsf.edu

19105 DiagnosticNCT04019002 Chang, Susan Evaluating hyperpolarized and proton brain metabolism in patients with glioblastoma 1-877-827-3222

17873 DiagnosticNCT03157167 Leslie, Kieron An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV)Injection and a Comparison to Subcutaneous (SC) Injection in Human Immunodeficiency Virus(HIV) Subjects Diagnosed with Kaposi Sarcoma (KS)

vasiliki.stamatopoulou@ucsf.edu

16753 Supportive CareMelisko, Michelle A Pilot Study of the Pathways Program for Cancer Survivors at the UCSF Breast Care Center 1-877-827-3222

18863 TreatmentNCT03767348 Tsai, Katy An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination withPD1 Blockade in Patients with Solid Tumors

Ann.Tittiger@ucsf.edu

Page 20last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

19521 TreatmentNCT03869190 Friedlander, Terence A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy andSafety of Multiple Immunotherapy-based Treatment Combinations in Patients With LocallyAdvanced or Metastatic Urothelial Carcinoma after Failure With Platinum-ContainingChemotherapy (MORPHEUS-mUC)

lani.bradish@ucsf.edu

19202 TreatmentNCT03690388 Kang, Hyunseok A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) inSubjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed afterPrior VEGFR-Targeted Therapy

carter.hultman@ucsf.edu

10082 OtherNCT01200017 Dvorak, Christopher An Expanded Access Study of the Feasibility of Using the CliniMACS® Device for CD34+ CellSelection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative DonorStem Cell Transplant Recipients

1-877-827-3222

17872 TreatmentNCT03316274 Wang, Chia-Ching Phase 1 Study to Evaluate the Safety, Feasibility, and Immunologic Correlatives of Intra-lesionalNivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

1-877-827-3222

17-21815 PreventionNCT03036930 Roll, Garrett Immunogenicity of Nonavalent HPV Vaccine Administered prior to Renal Transplantation inAdults: A Prospective, Single-Arm, Multi-Center Clinical Trial

Kristina.Johnson@UCSF.EDU;Rodney.Rogers@UCSF.EDU

CTSU-EA1151 ScreeningNCT03233191 Freimanis, Rita Tomosynthesis Mammographic Imaging Screening Trial (TMIST) 1-877-827-3222

19104 TreatmentNCT03345095 Butowski, Nicholas A Phase III Trial of Marizomib in Combination With Standard Temozolomide-basedRadiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone inPatients With Newly Diagnosed Glioblastoma

1-877-827-3222

18409 Supportive CareRowen, Tami Vaginal Dilator Use after Pelvic Radiation 1-877-827-3222

19556 TreatmentNCT03554317 Aggarwal, Rahul COMbination of Bipolar Androgen Therapy and Nivolumab in Patients with MetastaticCastration-Resistant Prostate Cancer (COMBAT-CRPC)

lani.bradish@ucsf.edu

197016 TreatmentNCT03970382 Oh, David A PHASE 1A/1B, OPEN-LABEL FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITYAND FEASIBILITY OF GENE-EDITED AUTOLOGOUS NeoTCR-T CELLS (NeoTCR-P1)ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH ANTI-PD-1 TOPATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Joanne.Otani@ucsf.edu;andrew.chon@ucsf.edu

194519 TreatmentNCT04003636 Kelley, Robin A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatinversus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advancedand/or Unresectable Biliary Tract Carcinoma

kelly.bauer@ucsf.edu

SWOG-LUNGMAP

ScreeningNCT03851445 Eftimie, Bogdan A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

chetali_gupta@whhs.com

ALLIANCE--A151216

ScreeningNCT02194738 Chee, Karen Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) lisa.tan@ucsf.edu

ALLIANCE-A011106

TreatmentNCT01953588 Chee, Karen ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancerNeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study

1-877-827-3222

18405 ScreeningMartin, Jeffrey Prevention and early detection of cervical cancer through self-administered screening in thecommunity

1-877-827-3222

Page 21last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

161016 DiagnosticChang, Susan Non-Invasive Characterization of Lower Grade Glioma 1-877-827-3222

19101 TreatmentNCT02655601 Butowski, Nicholas A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With ConcurrentRadiation Therapy, Temozolomide, and BMX-001

1-877-827-3222

19403 TreatmentNCT03737643 Alvarez, Edwin A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab inCombination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab,Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).

1-877-827-3222

19404 TreatmentNCT03398655 Alvarez, Edwin A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of OfranergeneObadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for theTreatment of Recurrent Platinum-Resistant Ovarian Cancer

1-877-827-3222

189513 TreatmentNCT03948763 Munster, Pamela A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants WithKRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer orPancreatic Adenocarcinoma

denisha.otis@ucsf.edu

19552 TreatmentNCT03570619 Chou, Jonathan IMPACT: Immunotherapy in Patients with Metastatic Cancers and CDK12 Mutations lani.bradish@ucsf.edu

19851 TreatmentNCT03815058 Daud, Adil A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY ANDSAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUSPEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCEDMELANOMA

Ann.Tittiger@ucsf.edu

19954 TreatmentNCT03834948 Munster, Pamela A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluatethe Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of AO-176

ann.chan@ucsf.edu

19558 TreatmentNCT03834506 Fong, Lawrence A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel PlusPrednisone Versus Placebo Plus Docetaxel Plus Prednisone in Participants WithChemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who HaveProgressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)

1-877-827-3222

ECOG-ACRIN--E4512

TreatmentNCT02201992 Chee, Karen A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer:Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic LymphomaKinase (ALK) Fusion Protein

1-877-827-3222

EA-RP6530-1803-AI

TreatmentNCT03711604 Ai, Weiyun Expanded Access: An Open label, Compassionate Use Study of Tenalisib (RP6530) in Patientscurrently receiving treatment on Tenalisib trials in Hematological Malignancies

1-877-827-3222

18-24443 TreatmentNCT03475212 Dvorak, Christopher Antiviral Cellular Therapy for Enhancing T-Cell Reconstitution before or after HematopoieticStem Cell Transplantation (ACES) PBMTC SUP1701

magruderk@radonc.ucsf.edu

184511 Health ServicesResearch

NCT03867916 Nguyen, Tung The Patient Cancer OUtreach, Navigation, Technology, and Support (Patient COUNTS) Project:Addressing Care for Asian Americans with Cancer

1-877-827-3222

Page 22last updated 6/1/2020

Adult Interventional TrialsJune 2020

Study ContactTitleClinicalTrials.govProtocol

UCSF ProtocolNo.

PI Name Protocol Type

19652 TreatmentNCT03785964 Okimoto, Ross A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat VersusPlacebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

janna.blaauw@ucsf.edu;lisa.tan@ucsf.edu

19955 TreatmentNCT03928314 Munster, Pamela An Open-label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patientswith Advanced or Metastatic Solid Tumors

ann.chan@ucsf.edu

19206 TreatmentNCT03969004 Algazi, Alain A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versusPlacebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous SquamousCell Carcinoma

1-877-827-3222

19207 TreatmentNCT04119453 Kang, Hyunseok A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib inSubjects With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) of All Anatomic Sites ofOrigin

1-877-827-3222

EA-MAP-12519-ANDREADIS

OtherNCT03601442 Andreadis,Charalambos

Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblasticleukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis productand/or manufactured tisagenlecleucel out of specification for commercial release

1-877-827-3222

ALLIANCE--A081105

TreatmentNCT02193282 Chee, Karen RANDOMIZED STUDY OF ERLOTINIB VS OBSERVATION IN PATIENTS WITHCOMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANTNON-SMALL CELL LUNG CANCER (NSCLC)

lisa.tan@ucsf.edu

18801 Supportive CareNCT03905720 Chao, Maria Non-pharmacologic approaches to relieve pain and symptom distress among diversehospitalized cancer patients

1-877-827-3222

Page 23last updated 6/1/2020